Astellas Pharma Inc. (4503)

Basic

  • Market Cap

    ¥3,002.36B

  • EV

    ¥3,590.05B

  • Shares Out

    1,792.99M

  • Revenue

    ¥1,543.32B

  • Employees

    14,484

Margins

  • Gross

    81.76%

  • EBITDA

    16.13%

  • Operating

    7.57%

  • Pre-Tax

    1.67%

  • Net

    0.27%

  • FCF

    11.49%

Returns (5Yr Avg)

  • ROA

    7.23%

  • ROTA

    20.08%

  • ROE

    11.46%

  • ROCE

    16.15%

  • ROIC

    12.43%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    ¥2,252

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    ¥285.44B

  • Net Debt

    ¥587.7B

  • Debt/Equity

    0.58

  • EBIT/Interest

    26.98

Growth (CAGR)

  • Rev 3Yr

    7.19%

  • Rev 5Yr

    3.4%

  • Rev 10Yr

    3.1%

  • Dil EPS 3Yr

    -68.52%

  • Dil EPS 5Yr

    -53.71%

  • Dil EPS 10Yr

    -23.82%

  • Rev Fwd 2Yr

    5.17%

  • EBITDA Fwd 2Yr

    27.97%

  • EPS Fwd 2Yr

    31.4%

  • EPS LT Growth Est

    14.2%

Dividends

  • Yield

  • Payout

    2,783.06%

  • DPS

    ¥65

  • DPS Growth 3Yr

    16.6%

  • DPS Growth 5Yr

    11.93%

  • DPS Growth 10Yr

    9.6%

  • DPS Growth Fwd 2Yr

    11.7%

Select a metric from the list below to chart it

Mar '14

Mar '15

Mar '16

Mar '17

Mar '18

Mar '19

Mar '20

Mar '21

Mar '22

Mar '23

LTM

Total Revenues

1,306,348

1,300,843

1,249,528

1,296,163

1,518,619

1,543,324

Total Revenues % Chg.

0.5%

-0.4%

-3.9%

3.7%

17.2%

5.1%

Cost of Goods Sold, Total

292,050

276,739

246,063

253,009

288,353

281,536

Gross Profit

1,014,298

1,024,104

1,003,465

1,043,154

1,230,266

1,261,788

Selling General & Admin Expenses, Total

490,263

499,295

504,316

548,840

630,272

706,256

R&D Expenses

208,682

224,226

224,489

246,010

276,128

286,410

Depreciation & Amortization

35,212

21,164

23,763

28,283

38,436

75,435

Other Operating Expenses

-2,275

11,936

-35

1,876

53,778

76,890

Other Operating Expenses, Total

731,882

756,621

752,533

825,009

998,614

1,144,991

Operating Income

282,416

267,483

250,932

218,145

231,652

116,797

Interest Expense, Total

-2,232

-2,118

-2,315

-3,217

-4,329

Interest And Investment Income

2,770

2,248

760

862

5,253

6,918

Net Interest Expenses

2,770

16

-1,358

-1,453

2,036

2,589

Income (Loss) On Equity Invest.

-1,627

-1,660

478

489

1,260

-572

Currency Exchange Gains (Loss)

735

-8,928

-2,332

8,172

-10,124

-10,124

Other Non Operating Income (Expenses)

2,286

1,342

72

-2,431

2,303

2,303

EBT, Excl. Unusual Items

286,580

258,253

247,792

222,922

227,127

110,993

Restructuring Charges

-19,678

-1,829

-9,293

-19,556

-4,510

-4,510

Gain (Loss) On Sale Of Investments

5,812

10,558

5,084

-5,007

-5,007

Gain (Loss) On Sale Of Assets

3,923

24

24,234

212

9,739

Asset Writedown

-11,446

-13,796

-101,746

-74,850

-83,964

-83,964

Legal Settlements

-12,301

-1,201

-2,012

-948

-1,497

-1,497

EBT, Incl. Unusual Items

248,967

245,350

145,323

156,886

132,361

25,754

Income Tax Expense

26,702

49,939

24,734

32,800

33,647

21,556

Earnings From Continuing Operations

222,265

195,411

120,589

124,086

98,714

4,198

Net Income

222,265

195,411

120,589

124,086

98,714

4,198

Net Income to Common Incl Extra Items

222,265

195,411

120,589

124,086

98,714

4,198

Net Income to Common Excl. Extra Items

222,265

195,411

120,589

124,086

98,714

4,198

Total Shares Outstanding

1,885.8

1,857.5

1,853

1,827.1

1,796.8

1,793

Weighted Avg. Shares Outstanding

1,931.9

1,876.2

1,857.1

1,849.7

1,820

1,797.4

Weighted Avg. Shares Outstanding Dil

1,933.7

1,877.5

1,858.2

1,850.6

1,825.1

1,806.6

EPS

115.1

104.2

64.9

67.1

54.2

2.3

EPS Diluted

114.9

104.1

64.9

67.1

54.1

2.3

EBITDA

345,874

333,879

323,584

297,829

337,390

249,011